Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CLOZAPINE-INDUCED AGRANULOCYTOSIS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 53 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Reitzle, K; Warnke, A; Wewetzer, C; Muller, H
      Agranulocytosis in a schizophrenic child receiving clozapine therapy - clinical picture and therapy. a case report

      ZEITSCHRIFT FUR KINDER-UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE
    2. Palmblad, J; Papadaki, HA; Eliopoulos, G
      Acute and chronic neutropenias. What is new?

      JOURNAL OF INTERNAL MEDICINE
    3. Coleman, MD
      Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention

      TOXICOLOGY
    4. Kodesh, A; Finkel, B; Lerner, AG; Kretzmer, G; Sigal, M
      Dose-dependent olanzapine-associated leukopenia: three case reports

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    5. Buchman, N; Strous, RD; Ulman, AM; Lerner, M; Kotler, M
      Olanzapine-induced leukopenia with human leukocyte antigen profiling

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    6. Pickar, D; Rubinow, K
      Pharmacogenomics of psychiatric disorders

      TRENDS IN PHARMACOLOGICAL SCIENCES
    7. Reznik, I; Mester, R
      Genetic factors in clozapine-induced agranulocytosis

      ISRAEL MEDICAL ASSOCIATION JOURNAL
    8. Felber, W; Naumann, R; Schuler, U; Fulle, M; Reuster, T; Garcia, K; Heilemann, H
      Are there genetic determinants of olanzapine-induced agranulocytosis?

      PHARMACOPSYCHIATRY
    9. Dettling, M
      Are there genetic determinants of olanzapine-induced agranulocytosis? Reply of the authors

      PHARMACOPSYCHIATRY
    10. Naisbitt, DJ; Gordon, SF; Pirmohamed, M; Park, BK
      Immunological principles of adverse drug reactions - The initiation and propagation of immune responses elicited by drug treatment

      DRUG SAFETY
    11. Lai, WG; Gardner, I; Zahid, N; Uetrecht, JP
      Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: Implications for fluperlapine-induced agranulocytosis

      DRUG METABOLISM AND DISPOSITION
    12. Pollmacher, T; Haack, M; Schuld, A; Kraus, T; Hinze-Selch, D
      Effects of antipsychotic drugs on cytokine networks

      JOURNAL OF PSYCHIATRIC RESEARCH
    13. Vial, T; Gallant, C; Choquet-Kastylevsky, G; Descotes, J
      Treatment of drug-induced agranulocytosis with haematopoietic growth factors - A review of the clinical experience

      BIODRUGS
    14. Uetrecht, JP
      New concepts in immunology relevant to idiosyncratic drug reactions: The "danger hypothesis" and innate immune system

      CHEMICAL RESEARCH IN TOXICOLOGY
    15. Beauchesne, MF; Shalansky, SJ
      Nonchemotherapy drug-induced agranulocytosis: A review of 118 patients treated with colony-stimulating factors

      PHARMACOTHERAPY
    16. Steinwachs, A; Grohmann, R; Pedrosa, F; Ruther, E; Schwerdtner, I
      Two cases of olanzapine-induced reversible neutropenia

      PHARMACOPSYCHIATRY
    17. Dettling, M; Cascorbi, I; Hellweg, R; Deicke, U; Weise, L; Muller-Oerlinghausen, B
      Genetic determinants of drug-induced agranulocytosis: Potential risk of olanzapine?

      PHARMACOPSYCHIATRY
    18. Lorenz, M; Evering, WE; Provencher, A; Blue, JT; Lewis, HB; Hazelette, JR; Rajagopalan, P; Meunier, PC; Car, BD
      Atypical antipsychotic-induced neutropenia in dogs

      TOXICOLOGY AND APPLIED PHARMACOLOGY
    19. Grube, M; Kurzweg, A
      Leucopenia under butyrophenones - successful treatment of severe schizophrenic psychoses by giving benperidol intermittent every other day

      NERVENARZT
    20. Marsh, JCW; Chowdry, J; Parry-Jones, N; Ellis, SW; Muir, KR; Gordon-Smith, EC; Tucker, GT
      Study of the association between cytochromes P450 2D6 and 2E1 genotypes and the risk of drug and chemical induced idiosyncratic aplastic anaemia

      BRITISH JOURNAL OF HAEMATOLOGY
    21. Liegeois, JF; Bruhwyler, J; Petit, C; Damas, J; Delarge, J; Geczy, J; Kauffmann, JM; Lamy, M; Meltzer, H; Mouithys-Mickalad, A
      Oxidation sensitivity may be a useful tool for the detection of the hematotoxic potential of newly developed molecules: Application to antipsychotic drugs

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    22. NAVAS F; TANG FLM; SCHALLER LT; NORMAN MH
      ANALOGS OF THE POTENTIAL ANTIPSYCHOTIC AGENT 1192U90 - AMIDE MODIFICATIONS

      Bioorganic & medicinal chemistry
    23. VANDERKLAUW MM; WILSON JHP; STRICKER BHC
      DRUG-ASSOCIATED AGRANULOCYTOSIS - 20 YEARS OF REPORTING IN THE NETHERLANDS (1974-1994)

      American journal of hematology
    24. KING DJ; WAGER E
      HEMATOLOGICAL SAFETY OF ANTIPSYCHOTIC-DRUGS

      JOURNAL OF PSYCHOPHARMACOLOGY
    25. FINKEL B; LERNER A; OYFFE I; RUDINSKI D; SIGAL M; WEIZMAN A
      OLANZAPINE TREATMENT IN PATIENTS WITH TYPICAL AND ATYPICAL NEUROLEPTIC-ASSOCIATED AGRANULOCYTOSIS

      International clinical psychopharmacology
    26. ANDRES E; KURTZ JE; OFFNER C; GRUNENBERGER F; WEBER JC; KALTENBACH G; NEYROLLES N; MALOISEL F
      DRUG-INDUCED AGRANULOCYTOSIS - EXPERIENCE AT THE STRASBOURG-TEACHING-HOSPITAL

      La Semaine des hopitaux de Paris
    27. CLAVIJO OP; DELGADO JC; AWDEH ZL; FICI D; TURBAY D; ALPER CA; TRUEDSSON L; YUNIS EJ
      HLA-CW ALLELES ASSOCIATED WITH HLA EXTENDED HAPLOTYPES AND C2 DEFICIENCY

      Tissue antigens
    28. FAVATIER F; BORNMAN L; HIGHTOWER LE; GUNTHER E; POLLA BS
      VARIATION IN HSP GENE-EXPRESSION AND HSP POLYMORPHISM - DO THEY CONTRIBUTE TO DIFFERENTIAL DISEASE SUSCEPTIBILITY AND STRESS TOLERANCE

      Cell stress & chaperones
    29. IHAN O; BEKSAC M; ARSLAN O; OZCAN M; KOC H; AKAN H; GURMAN G; KONUK N; UYSAL A
      HLA DR2 - A PREDICTIVE MARKER IN RESPONSE TO CYCLOSPORINE THERAPY IN APLASTIC-ANEMIA

      International journal of hematology
    30. BUCKLEY PF
      NEW DIMENSIONS IN THE PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIA AND RELATED PSYCHOSES

      Journal of clinical pharmacology
    31. WATERS CH
      MANAGING THE LATE COMPLICATIONS OF PARKINSONS-DISEASE

      Neurology
    32. HERZ MI; LIBERMAN RP; LIEBERMAN JA; MARDER SR; MCGLASHAN TH; WYATT RJ; WANG P
      PRACTICE GUIDELINE FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA

      The American journal of psychiatry
    33. VLAHOV V; BACRACHEVA N; TONTCHEVA D; NAUMOVA E; MAVRUDIEVA M; ILIEVA P; MICHAILOVA A
      GENETIC-FACTORS AND RISK OF AGRANULOCYTOSIS FROM METAMIZOL

      Pharmacogenetics
    34. UETRECHT JP
      REACTIVE METABOLITES AND AGRANULOCYTOSIS

      European journal of haematology
    35. UMBRICHT D; KANE JM
      MEDICAL COMPLICATIONS OF NEW ANTIPSYCHOTIC-DRUGS

      Schizophrenia bulletin
    36. LADEB S; HERBRECHT R; ESCUDIER B; DHEDIN N; CORDONNIER C
      GROWTH-FACTORS AND INFECTION

      Medecine et maladies infectieuses
    37. VIAL T; POFILET C; PHAM E; PAYEN C; EVREUX JC
      DRUG-INDUCED AGRANULOCYTOSIS

      Therapie
    38. KANE JM
      DRUG-THERAPY - SCHIZOPHRENIA

      The New England journal of medicine
    39. GLASER J; SCHLEIPEN W
      THERAPY OF A DOXEPINE-INDUCED AGRANULOCYT OSIS BY MEANS OF G-CSF

      Die medizinische Welt
    40. OWENS DGC
      ADVERSE-EFFECTS OF ANTIPSYCHOTIC AGENTS - DO NEWER AGENTS OFFER ADVANTAGES

      Drugs
    41. OWENS DGC
      ADVANCES IN PSYCHOPHARMACOLOGY - SCHIZOPHRENIA

      British Medical Bulletin
    42. PANTELIS C; BARNES TRE
      DRUG STRATEGIES AND TREATMENT-RESISTANT SCHIZOPHRENIA

      Australian and New Zealand Journal of Psychiatry
    43. BREIER A
      THE MANAGEMENT OF TREATMENT-RESISTANT SCHIZOPHRENIA

      Current opinion in psychiatry
    44. WHITWORTH AB; FLEISCHHACKER WW
      ADVERSE-EFFECTS OF ANTIPSYCHOTIC-DRUGS

      International clinical psychopharmacology
    45. KANE JM; MCGLASHAN TH
      TREATMENT OF SCHIZOPHRENIA

      Lancet
    46. SPRIKKELMAN A; DEWOLF JTM; VELLENGA E
      THE APPLICATION OF HEMATOPOIETIC GROWTH-FACTORS IN DRUG-INDUCED AGRANULOCYTOSIS - A REVIEW OF 70 CASES

      Leukemia
    47. MA J; LIEBERMAN JA
      AGRANULOCYTOSIS - INCIDENCE AND RISK-FACTORS

      The Journal of clinical psychiatry
    48. FRAMPTON JE; LEE CR; FAULDS D
      FILGRASTIM - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY IN NEUTROPENIA

      Drugs
    49. NIMER SD; IRELAND P; MESHKINPOUR A; FRANE M
      AN INCREASED HLA DR2 FREQUENCY IS SEEN IN APLASTIC-ANEMIA PATIENTS

      Blood
    50. ZALEON CR; GUTHRIE SK
      ANTIPSYCHOTIC DRUG-USE IN OLDER ADULTS

      American journal of hospital pharmacy
    51. ELLENBROEK BA
      TREATMENT OF SCHIZOPHRENIA - A CLINICAL AND PRECLINICAL EVALUATION OFNEUROLEPTIC DRUGS

      Pharmacology & therapeutics
    52. LANDY DA
      HLA TYPING COSTS

      The Journal of clinical psychiatry
    53. KENDRA JR; RUGMAN FP; FLAHERTY TA; MYERS A; HORSFIELD N; BARTON A; RUSSELL L
      1ST USE OF G-CSF IN CHLOROPROMAZINE-INDUCED AGRANULOCYTOSIS - A REPORT OF 2 CASES

      Postgraduate medical journal


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/02/20 alle ore 13:06:09